CA2225627A1 - Derives de l'azetidinone pour le traitement de l'atherosclerose - Google Patents
Derives de l'azetidinone pour le traitement de l'atherosclerose Download PDFInfo
- Publication number
- CA2225627A1 CA2225627A1 CA002225627A CA2225627A CA2225627A1 CA 2225627 A1 CA2225627 A1 CA 2225627A1 CA 002225627 A CA002225627 A CA 002225627A CA 2225627 A CA2225627 A CA 2225627A CA 2225627 A1 CA2225627 A1 CA 2225627A1
- Authority
- CA
- Canada
- Prior art keywords
- oxoazetidin
- diastereoisomer
- benzylsulphinyl
- acetamide
- hexyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
- C07D205/085—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a nitrogen atom directly attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
- C07D205/09—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4
- C07D205/095—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4 and with a nitrogen atom directly attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
L'invention concerne les composés de l'azétidinone présentant la formule (I). Dans cette formule, R?1¿ et R?2¿ peuvent être identiques ou différents, et sont chacun sélectionnés parmi de l'hydrogène, de l'halogène ou de l'alkyle (C¿1-8?); R?4¿ et R?5¿ peuvent être semblables ou différents et sont chacun sélectionnés parmi de l'hydrogène, de l'alkyle (C¿1-6?), de l'alcényle (C¿2-6?), de l'aryle, de l'arylalkyle (C¿1-4?) et de l'hétéroarylalkyle (C¿1-4?), qui peuvent être tous éventuellement substitués, ou R?4¿ et R?5¿ peuvent être liés ensemble pour former le reste d'un noyau de cycloalkyle (C¿3-7?); X est un groupe de liaison; Y est un groupe aryle éventuellement substitué; Z est de l'oxygène et R?3¿ est de l'alkyle (C¿1-8?), du cycloalkyle (C¿3-8?), du cycloalkyle(C¿3-8?)alkyle(C¿1-6?), de l'hétéroaryle, de l'hétéroarylalkyle (C¿1-4?), de l'aryle, ou de l'arylalkyle (C¿1-4?) qui peuvent être tous éventuellement substitués, ou Z désigne à S(O)n où n vaut 0, 1 ou 2 et R?3¿ est de l'alkyle (C¿1-8?), du cycloalkyle (C¿3-8?), du cycloalkyle (C¿3-8?), de l'aryle, de l'alkyle (C¿1-4?) d'aryle, de l'hétéroaryle, ou de l' hétéroarylalkyle (C¿1-4?), qui peuvent tous être éventuellement substitués. Ces composés sont des inhibiteurs de l'enzyme Lp PLA2 et sont particulièrement utiles dans le traitement de l'athérosclérose.
Applications Claiming Priority (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9513442.5 | 1995-07-01 | ||
GBGB9513442.5A GB9513442D0 (en) | 1995-07-01 | 1995-07-01 | Novel compounds |
GB9515056.1 | 1995-07-22 | ||
GBGB9515056.1A GB9515056D0 (en) | 1995-07-22 | 1995-07-22 | Novel compounds |
GBGB9515206.2A GB9515206D0 (en) | 1995-07-25 | 1995-07-25 | Novel compounds |
GB9515206.2 | 1995-07-25 | ||
GB9516985.0 | 1995-08-18 | ||
GBGB9516985.0A GB9516985D0 (en) | 1995-08-18 | 1995-08-18 | Novel compounds |
GBGB9525132.8A GB9525132D0 (en) | 1995-12-08 | 1995-12-08 | Novel compounds |
GB9525132.8 | 1995-12-08 | ||
GB9608650.9 | 1996-04-26 | ||
GBGB9608651.7A GB9608651D0 (en) | 1996-04-26 | 1996-04-26 | Novel compounds |
GB9608651.7 | 1996-04-26 | ||
GBGB9608650.9A GB9608650D0 (en) | 1996-04-26 | 1996-04-26 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2225627A1 true CA2225627A1 (fr) | 1997-01-23 |
Family
ID=27562921
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002225627A Abandoned CA2225627A1 (fr) | 1995-07-01 | 1996-06-20 | Derives de l'azetidinone pour le traitement de l'atherosclerose |
Country Status (23)
Country | Link |
---|---|
EP (1) | EP0840725A1 (fr) |
JP (1) | JP2002515852A (fr) |
KR (1) | KR19990028630A (fr) |
CN (1) | CN1197452A (fr) |
AP (1) | AP728A (fr) |
AU (1) | AU708032B2 (fr) |
BG (1) | BG102214A (fr) |
BR (1) | BR9609445A (fr) |
CA (1) | CA2225627A1 (fr) |
CZ (1) | CZ422197A3 (fr) |
EA (1) | EA199800109A1 (fr) |
HU (1) | HUP9901153A3 (fr) |
IL (1) | IL122650A0 (fr) |
MA (1) | MA23922A1 (fr) |
MX (1) | MX9800186A (fr) |
NO (1) | NO976158L (fr) |
NZ (1) | NZ311684A (fr) |
OA (1) | OA10648A (fr) |
PE (1) | PE8998A1 (fr) |
PL (1) | PL324240A1 (fr) |
SK (1) | SK178497A3 (fr) |
TR (1) | TR199701762T1 (fr) |
WO (1) | WO1997002242A1 (fr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0869943A1 (fr) * | 1995-12-08 | 1998-10-14 | Smithkline Beecham Plc | Derives de beta-lactame monocycliques utilises dans le traitement de l'atherosclerose |
GB9608649D0 (en) * | 1996-04-26 | 1996-07-03 | Smithkline Beecham Plc | Novel compounds |
BR9709196A (pt) * | 1996-04-26 | 1999-05-25 | Smithkline Beecham Plc | Derivados de azetidinona para o tratamento de aterosclerose |
EP1686119B1 (fr) | 2000-02-16 | 2009-07-29 | Smithkline Beecham Plc | Dérivés de Pyrimidine-5-one comme inhibiteurs LDL-PLA2 |
GB0024808D0 (en) | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
AU2008251467B2 (en) | 2007-05-11 | 2014-07-31 | The Trustees Of The University Of Pennsylvania | Methods of treatment of skin ulcers |
KR101690390B1 (ko) | 2007-05-11 | 2016-12-27 | 토마스 제퍼슨 유니버시티 | 신경변성 질환 및 장애의 치료 및 예방 방법 |
US8962633B2 (en) | 2007-05-11 | 2015-02-24 | Thomas Jefferson University | Methods of treatment and prevention of metabolic bone diseases and disorders |
CA2820408C (fr) | 2010-12-06 | 2018-03-06 | Glaxo Group Limited | Composes de pyrimidinone utiles dans le traitement de maladies ou d'etats pathologiques induits par la lp-pla2 |
EP2651403B1 (fr) | 2010-12-17 | 2020-12-02 | Glaxo Group Limited | Procédés de traitement et de prévention de maladies oculaires |
WO2013000267A1 (fr) | 2011-06-27 | 2013-01-03 | 中国科学院上海药物研究所 | Composé hétérocyclique azole, procédé de préparation, composition pharmaceutique et utilisation |
KR20140059203A (ko) | 2011-07-27 | 2014-05-15 | 글락소 그룹 리미티드 | 2,3-디히드로이미다조[1,2-c]피리미딘-5(1h)-온 화합물의 lp-pla2 억제제로서의 용도 |
EP2736908A1 (fr) | 2011-07-27 | 2014-06-04 | Glaxo Group Limited | Composés pyrimidones bicycliques |
KR20150111356A (ko) | 2013-01-25 | 2015-10-05 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 화합물 |
MX2015009633A (es) | 2013-01-25 | 2015-11-30 | Glaxosmithkline Ip Dev Ltd | Inhibidores de fosfolipasa a2 asociada con lipoproteinas basados en 2,3-dihidroimidazol[1,2-c] pirimidin-5(1h)-ona. |
AU2014210260B2 (en) | 2013-01-25 | 2016-08-04 | Glaxosmithkline Intellectual Property Development Limited | Bicyclic pyrimidone compounds as inhibitors of Lp-PLA2 |
WO2016012917A1 (fr) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | Dérivés 1,2,3,5-tétrahydro-imidazo [1,2-c]pyrimidine utiles pour le traitement de maladies et de troubles médiés par la lp-pla2 |
WO2016012916A1 (fr) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | Dérivés 1,2,3,5-tétrahydro-imidazo [1,2-c]pyrimidine utiles pour le traitement de maladies et de troubles médiés par la lp-pla2 |
JP2023500710A (ja) | 2019-11-09 | 2023-01-10 | シャンハイ エスアイエムアール バイオテクノロジー カンパニー リミテッド | 三環式ジヒドロイミダゾピリミドン誘導体、その調製方法、その医薬組成物及び使用 |
CN115304620A (zh) | 2021-05-07 | 2022-11-08 | 上海赛默罗生物科技有限公司 | 嘧啶酮衍生物、其制备方法、药物组合物和用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4680391A (en) * | 1983-12-01 | 1987-07-14 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
IL89835A0 (en) * | 1988-04-11 | 1989-12-15 | Merck & Co Inc | Substituted azetidinones,their preparation and pharmaceutical compositions containing them |
IL99658A0 (en) * | 1990-10-15 | 1992-08-18 | Merck & Co Inc | Substituted azetidinones and pharmaceutical compositions containing them |
GB9421816D0 (en) * | 1994-10-29 | 1994-12-14 | Smithkline Beecham Plc | Novel compounds |
AP9701007A0 (en) * | 1994-12-22 | 1997-07-31 | Smithkline Beecham Plc | Substituted azetidin-2-ones for treatment of atherosclerosis. |
-
1996
- 1996-06-20 TR TR97/01762T patent/TR199701762T1/xx unknown
- 1996-06-20 SK SK1784-97A patent/SK178497A3/sk unknown
- 1996-06-20 IL IL12265096A patent/IL122650A0/xx unknown
- 1996-06-20 CN CN96196661A patent/CN1197452A/zh active Pending
- 1996-06-20 EP EP96922030A patent/EP0840725A1/fr not_active Withdrawn
- 1996-06-20 AP APAP/P/1997/001161A patent/AP728A/en active
- 1996-06-20 PL PL96324240A patent/PL324240A1/xx unknown
- 1996-06-20 EA EA199800109A patent/EA199800109A1/ru unknown
- 1996-06-20 CA CA002225627A patent/CA2225627A1/fr not_active Abandoned
- 1996-06-20 HU HU9901153A patent/HUP9901153A3/hu unknown
- 1996-06-20 BR BR9609445A patent/BR9609445A/pt unknown
- 1996-06-20 WO PCT/EP1996/002765 patent/WO1997002242A1/fr not_active Application Discontinuation
- 1996-06-20 KR KR1019970709952A patent/KR19990028630A/ko not_active Application Discontinuation
- 1996-06-20 AU AU63050/96A patent/AU708032B2/en not_active Ceased
- 1996-06-20 JP JP50477297A patent/JP2002515852A/ja active Pending
- 1996-06-20 CZ CZ974221A patent/CZ422197A3/cs unknown
- 1996-06-20 NZ NZ311684A patent/NZ311684A/xx unknown
- 1996-06-28 MA MA24298A patent/MA23922A1/fr unknown
- 1996-06-28 PE PE1996000496A patent/PE8998A1/es not_active Application Discontinuation
-
1997
- 1997-12-30 NO NO976158A patent/NO976158L/no unknown
- 1997-12-31 OA OA70172A patent/OA10648A/en unknown
-
1998
- 1998-01-07 MX MX9800186A patent/MX9800186A/es unknown
- 1998-01-28 BG BG102214A patent/BG102214A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
BR9609445A (pt) | 1999-04-06 |
AP728A (en) | 1999-01-29 |
MA23922A1 (fr) | 1996-12-31 |
WO1997002242A1 (fr) | 1997-01-23 |
MX9800186A (es) | 1998-07-31 |
CN1197452A (zh) | 1998-10-28 |
EA199800109A1 (ru) | 1998-10-29 |
HUP9901153A3 (en) | 1999-11-29 |
HUP9901153A2 (hu) | 1999-08-30 |
PE8998A1 (es) | 1998-03-20 |
TR199701762T1 (xx) | 1998-05-21 |
SK178497A3 (en) | 1998-07-08 |
EP0840725A1 (fr) | 1998-05-13 |
IL122650A0 (en) | 1998-08-16 |
NZ311684A (en) | 2000-04-28 |
CZ422197A3 (cs) | 1998-06-17 |
AU6305096A (en) | 1997-02-05 |
OA10648A (en) | 2002-09-25 |
NO976158D0 (no) | 1997-12-30 |
AP9701161A0 (en) | 1998-01-31 |
NO976158L (no) | 1998-02-25 |
BG102214A (en) | 1998-08-31 |
PL324240A1 (en) | 1998-05-11 |
JP2002515852A (ja) | 2002-05-28 |
AU708032B2 (en) | 1999-07-29 |
KR19990028630A (ko) | 1999-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2225627A1 (fr) | Derives de l'azetidinone pour le traitement de l'atherosclerose | |
KR930008223B1 (ko) | 소염제 및 퇴화 억제제로서 유용한 치환된 아제티디논 | |
KR100235806B1 (ko) | 저콜레스테롤혈증 치료제로서 유용한 황 치환된 아제티디논 화합물 | |
NZ243669A (en) | Heterocyclyl-substituted beta-lactam derivatives pharmaceutical compositions | |
JPH11500415A (ja) | アテローム性動脈硬化症治療用置換アゼチジン−2−オン | |
US5229381A (en) | Substituted azetidinones as anti-inflammatory and antidegenerative agents | |
AU648345B2 (en) | New substituted azetidinones as anti-inflammatory and antidegenerative agents | |
HU227492B1 (en) | Intermediates for the preparation of agents having antifungal activity, processes for the preparation thereof | |
CN101657424A (zh) | 双重作用的抗高血压药剂 | |
JPH08507085A (ja) | アゼチジノンの合成方法 | |
JP2000509049A (ja) | アテローム性動脈硬化症の治療用アゼチジノン誘導体 | |
IE55839B1 (en) | Azetidine compounds | |
JP2000509063A (ja) | アテローム性動脈硬化症の治療用アゼチジノン誘導体 | |
WO1997021675A1 (fr) | Derives de beta-lactame monocycliques utilises dans le traitement de l'atherosclerose | |
JP3576193B2 (ja) | ビフェニルメチル置換バレリルアミド誘導体 | |
JPH11513704A (ja) | 酸性ピラゾールの新誘導体、それらの製造方法、それらの薬剤としての用途、それらの新規な用途並びにそれらを含有する製薬組成物 | |
JP2000501072A (ja) | イミダゾール−n−ベンジルジオキソールの新誘導体、それらの製造方法、それらの薬剤としての用途、製薬組成物及び新規な用途 | |
SK29295A3 (en) | 4-oxo-azetidine-2-sulphonic acid amides and their salts, process for their production and their use | |
CA2058603C (fr) | Polyhydroxymonoamides inhibiteurs de la renine | |
JP2001172245A (ja) | アミノブタン酸誘導体 | |
EP0218415A1 (fr) | Procédé pour la préparation de produits intermédiaires en vue de la préparation de 1-carbapénèmes et de 1-carbacéphèmes | |
JP2003212831A (ja) | アミノブタン酸誘導体 | |
KR20000065040A (ko) | 아테롬성동맥경화증치료를위한아제티디논유도체 | |
JPH054975A (ja) | トリアゾール抗真菌剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |